Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study

Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).

(2021) Mark Yarchoan et al.   JOURNAL OF CLINICAL ONCOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

(2021) Zhenggang Ren et al.   LANCET ONCOLOGY

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial

(2021) Qi-Jiong Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).

(2020) Li Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

ESMO Virtual Congress 2020

(2020) Katherine Gourd et al.   LANCET ONCOLOGY

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

(2019) MinKe He et al.   JAMA Oncology

The chances of hepatic resection curing hepatocellular carcinoma

(2019) Alessandro Cucchetti et al.   JOURNAL OF HEPATOLOGY

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View

(2019) Xu Yang et al.   JAMA Oncology

Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis

(2018) Jong Hwan Choi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma

(2018) Ning Lyu et al.   JOURNAL OF HEPATOLOGY

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?

(2018) Ze-Feng Zhang et al.   World Journal of Clinical Cases

FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma

(2017) Ning Lyu et al.   GUT

CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study

(2017) Jiliang Qiu et al.   JOURNAL OF CLINICAL ONCOLOGY

Reversibility of chemotherapy-related liver injury

(2017) Luca Vigano et al.   JOURNAL OF HEPATOLOGY

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

(2016) M. Ikeda et al.   ANNALS OF ONCOLOGY

Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas

(2016) Pinghua Yang et al.   ANNALS OF SURGERY

Location of a biliary leak after liver resection determines success of endoscopic treatment

(2016) Anja Schaible et al.   SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil

(2015) Kazuomi Ueshima et al.   Liver Cancer

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

(2013) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare

(2013) Fadia T. Shaya et al.   PHARMACOECONOMICS

Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy

(2012) Masatoshi Kudo   Liver Cancer

Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS)

(2011) Nuh N. Rahbari et al.   HPB

Predicting High Grade Lesions of Sinusoidal Obstruction Syndrome Related to Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases

(2010) Olivier Soubrane et al.   ANNALS OF SURGERY

Sinusoidal Obstruction Syndrome Impairs Long-Term Outcome of Colorectal Liver Metastases Treated with Resection after Neoadjuvant Chemotherapy

(2010) Dietmar Tamandl et al.   ANNALS OF SURGICAL ONCOLOGY

Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases

(2010) Yoji Kishi et al.   ANNALS OF SURGICAL ONCOLOGY

Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury

(2010) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy

(2009) Hiroshi Nakano et al.   ANNALS OF SURGERY

Portal Hypertension Associated With Oxaliplatin Administration: Clinical Manifestations of Hepatic Sinusoidal Injury

(2009) Julian H. Slade et al.   Clinical Colorectal Cancer